New Fund Offer (NFO) for both opens on September 1, 2021; closes on
September 14, 2021 for ETF and September 15, 2021 for Fund of Fund
Mirae Asset Investment Managers (India) Private Limited, one of the fastest growing fund houses in the country in the equities and debt segments, today announced the launch of India’s first passive products which aim to provide sector agnostic exposure to 50 Mega-cap companies of US*, ‘Mirae Asset S&P 500 Top 50 ETF’ , an open-ended scheme replicating/tracking S&P 500 Top 50 Total Return Index and ‘Mirae Asset S&P 500 Top 50 ETF Fund of Fund’ , an open-ended fund of fund scheme predominantly investing in Mirae Asset S&P 500 Top 50 ETF.
The NFO for both the funds will open for subscription on September 1, 2021. While Mirae Asset S&P 500 Top 50 ETF will close on September 14, 2021, Mirae Asset S&P 500 Top 50 ETF Fund of Fund will close on September 15, 2021.
Mirae Asset S&P 500 Top 50 ETF will be managed by Mr. Siddharth Srivastava, while Mirae Asset S&P 500 Top 50 ETF Fund of Fund will be managed by Ms. Ekta Gala. ‘Mirae Asset S&P 500 Top 50 ETF Fund of Fund’ will also offer investors Regular Plan and Direct Plan with Growth Option.
New Fund Offer opens on: September 01, 2021 | New Fund Offer closes on: September 14, 2021 Scheme re-opens for continuous Sale and
Repurchase: September 22, 2021. ETF Listing on exchange: Within 5 working days from the date of allotment.
• Returns that are commensurate with the performance of S&P 500 Top 50 Total Return Index subject to tracking error and foreign exchange movement
• Investments in equity securities covered by S&P 500 Top 50 Total Return Index
*Investors should consult their financial advisers if they are not clear about the suitability of the product
New Fund Offer opens on: September 01, 2021 | New fund Offer closes on: September 15, 2021
Scheme re-opens for continuous Sale and Repurchase: September 23, 2021
• To generate long term capital appreciation/income
• Investments predominantly in units of S&P 500 Top 50 ETF
*Investors should consult their financial advisers if they are not clear about the suitability of the product